ACT CAPITAL MANAGEMENT, LLC
13F Reported Value
ⓘ$127.2M
Holdings
56
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
ACT CAPITAL MANAGEMENT, LLC disclosed 56 positions worth $127.2M in its Form 13F-HR for Q1 2026, led by $KRYS (Krystal Biotech, Inc.) at 12.3% of the equity portfolio, followed by $CVX and $XOM. During the quarter the fund opened 20 new positions and exited 22 — including a new stake in $ALMS. The portfolio is most concentrated in Healthcare (61.6% of disclosed assets). All figures are sourced directly from ACT CAPITAL MANAGEMENT, LLC’s Form 13F-HR filing with the SEC under CIK 1442273.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 75.9#116
Quality
$15.6M60,477 sh - 54.7#1,197
Quality
$15.5M75,000 sh - 61.8#782
Quality
$11.9M70,000 sh - —
Quality
$10.5M91,675 sh - 68.4
Quality
$8.3M249,025 sh - —
Quality
$7.9M70,900 sh - 74.6
Quality
$6.9M33,000 sh - —
Quality
$6.8M209,300 sh - 74.4
Quality
$5.2M82,500 sh - 10.2
Quality
$5.1M70,900 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Krystal Biotech, Inc.$KRYS | 75.9#116 | $15.6M | 60,477 |
 CHEVRON CORP$CVX | 54.7#1,197 | $15.5M | 75,000 |
 EXXON MOBIL CORP$XOM | 61.8#782 | $11.9M | 70,000 |
 Celcuity Inc.$CELC | — | $10.5M | 91,675 |
 TG THERAPEUTICS, INC.$TGTX | 68.4 | $8.3M | 249,025 |
 Abivax S.A.$ABVX | — | $7.9M | 70,900 |
 AMAZON COM INC$AMZN | 74.6 | $6.9M | 33,000 |
 Viking Therapeutics, Inc.$VKTX | — | $6.8M | 209,300 |
 ARROWHEAD PHARMACEUTICALS, INC.$ARWR | 74.4 | $5.2M | 82,500 |
 NEKTAR THERAPEUTICS$NKTR | 10.2 | $5.1M | 70,900 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of ACT CAPITAL MANAGEMENT, LLC's 56 positions.
Showing top 10 of 56 holdings.
Sector Allocation
Healthcare
$78.4M
Energy
$31.1M
Consumer Discretionary
$7.1M
Technology
$6.4M
Materials
$2.3M
Financials
$1.4M
Consumer Staples
$268,350
Industrials
$208,800
Full Holdings — ACT CAPITAL MANAGEMENT, LLC (Q1 2026)
All 56 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $KRYS | Krystal Biotech, Inc. | $15.6M | 12.3% | -0% | 75.9 |
| 2 | $CVX | CHEVRON CORP | $15.5M | 12.2% | -4% | 54.7 |
| 3 | $XOM | EXXON MOBIL CORP | $11.9M | 9.3% | -15% | 61.8 |
| 4 | $CELC | Celcuity Inc. | $10.5M | 8.2% | +45% | — |
| 5 | $TGTX | TG THERAPEUTICS, INC. | $8.3M | 6.5% | -7% | 68.4 |
| 6 | $ABVX | Abivax S.A. | $7.9M | 6.2% | +11% | — |
| 7 | $AMZN | AMAZON COM INC | $6.9M | 5.4% | +34% | 74.6 |
| 8 | $VKTX | Viking Therapeutics, Inc. | $6.8M | 5.3% | +2% | — |
| 9 | $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $5.2M | 4.1% | +10% | 74.4 |
| 10 | $NKTR | NEKTAR THERAPEUTICS | $5.1M | 4.0% | +38% | 10.2 |
| 11 |  $CYTK | CYTOKINETICS INC | $4.3M | 3.3% | +0% | 28 |
| 12 |  $ALMS | ALUMIS INC. | $3.8M | 3.0% | NEW | 9.2 |
| 13 |  $ET | Energy Transfer LP | $2.6M | 2.0% | +0% | 64.5 |
| 14 |  $FCX | FREEPORT-MCMORAN INC | $2.3M | 1.8% | NEW | 73.1 |
| 15 |  $AAOI | APPLIED OPTOELECTRONICS, INC. | $2.2M | 1.7% | NEW | 40.6 |
| 16 |  $XENE | Xenon Pharmaceuticals Inc. | $1.9M | 1.5% | NEW | 12.9 |
| 17 |  $NUVB | Nuvation Bio Inc. | $1.2M | 1.0% | -52% | 29.5 |
| 18 |  $STAA | STAAR SURGICAL CO | $1.0M | 0.8% | +0% | 18 |
| 19 |  $PRAX | Praxis Precision Medicines, Inc. | $869,913 | 0.7% | +286% | — |
| 20 |  $GBTC | Grayscale Bitcoin Trust ETF | $812,504 | 0.6% | -55% | — |
| 21 |  $S | SentinelOne, Inc. | $699,384 | 0.6% | NEW | 41.4 |
| 22 |  $LITE | Lumentum Holdings Inc. | $632,484 | 0.5% | NEW | 63.4 |
| 23 |  $BE | Bloom Energy Corp | $609,705 | 0.5% | -65% | 54.4 |
| 24 |  $CRGY | Crescent Energy Co | $607,500 | 0.5% | -27% | 57.4 |
| 25 |  $KURA | Kura Oncology, Inc. | $600,807 | 0.5% | +0% | 9.1 |
| 26 |  $VIR | Vir Biotechnology, Inc. | $576,128 | 0.5% | NEW | 5.6 |
| 27 |  $CRCL | Circle Internet Group, Inc. | $572,460 | 0.5% | NEW | 44.8 |
| 28 |  $HCC | WARRIOR MET COAL, INC. | $558,900 | 0.4% | -50% | 42.1 |
| 29 |  $PATH | UiPath, Inc. | $555,000 | 0.4% | +6% | 67.7 |
| 30 |  $SRRK | Scholar Rock Holding Corp | $530,928 | 0.4% | -10% | — |
| 31 |  $WGS | GeneDx Holdings Corp. | $513,760 | 0.4% | +167% | 38.6 |
| 32 |  $MU | MICRON TECHNOLOGY INC | $506,760 | 0.4% | NEW | 88.4 |
| 33 |  $NVDA | NVIDIA CORP | $488,320 | 0.4% | NEW | 90.2 |
| 34 |  $REPL | Replimune Group, Inc. | $470,475 | 0.4% | +0% | — |
| 35 |  $RGNX | REGENXBIO Inc. | $469,280 | 0.4% | -32% | 26.9 |
| 36 |  $PALI | PALISADE BIO, INC. | $450,625 | 0.3% | +72% | — |
| 37 |  $OLMA | Olema Pharmaceuticals, Inc. | $372,750 | 0.3% | -53% | — |
| 38 |  $GLUE | Monte Rosa Therapeutics, Inc. | $370,125 | 0.3% | NEW | 18.1 |
| 39 |  $ONDS | Ondas Inc. | $339,000 | 0.3% | NEW | 31.8 |
| 40 |  $ACOG | Alpha Cognition Inc. | $282,735 | 0.2% | +0% | — |
| 41 |  $MBX | MBX Biosciences, Inc. | $268,650 | 0.2% | NEW | — |
| 42 |  $APC | ARKO Petroleum Corp. | $268,350 | 0.2% | NEW | — |
| 43 |  $KYTX | Kyverna Therapeutics, Inc. | $258,900 | 0.2% | +20% | — |
| 44 |  $RYZ | Ryerson Holding Corp | $242,784 | 0.2% | NEW | 43.2 |
| 45 |  $NKLR | Terra Innovatum Global N.V. | $208,800 | 0.2% | +0% | — |
| 46 |  $INCY | INCYTE CORP | $188,240 | 0.1% | NEW | 81.2 |
| 47 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $152,000 | 0.1% | +233% | — |
| 48 |  $VPG | Vishay Precision Group, Inc. | $130,260 | 0.1% | NEW | 33 |
| 49 |  $ESPR | Esperion Therapeutics, Inc. | $130,150 | 0.1% | +0% | 34.3 |
| 50 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $125,100 | 0.1% | +0% | — |
| 51 |  $LSPD | Lightspeed Commerce Inc. | $112,000 | 0.1% | +0% | — |
| 52 |  $CMPS | COMPASS Pathways plc | $85,715 | 0.1% | NEW | — |
| 53 |  $LTRX | LANTRONIX INC | $78,600 | 0.1% | NEW | 29.8 |
| 54 |  $SSYS | STRATASYS LTD. | $78,100 | 0.1% | +0% | — |
| 55 |  $HIMS | Hims & Hers Health, Inc. | $51,900 | 0.0% | NEW | 50.9 |
| 56 |  $PDSB | PDS Biotechnology Corp | $18,150 | 0.0% | +0% | — |
New Positions (20)
$ALMS ALUMIS INC.$3.8M$FCX FREEPORT-MCMORAN INC$2.3M$AAOI APPLIED OPTOELECTRONICS, INC.$2.2M$XENE Xenon Pharmaceuticals Inc.$1.9M$S SentinelOne, Inc.$699,384$LITE Lumentum Holdings Inc.$632,484$VIR Vir Biotechnology, Inc.$576,128$CRCL Circle Internet Group, Inc.$572,460$MU MICRON TECHNOLOGY INC$506,760$NVDA NVIDIA CORP$488,320$GLUE Monte Rosa Therapeutics, Inc.$370,125$ONDS Ondas Inc.$339,000$MBX MBX Biosciences, Inc.$268,650$APC ARKO Petroleum Corp.$268,350$RYZ Ryerson Holding Corp$242,784Exited Positions (22)
$GPCR Structure Therapeutics Inc.
$FIGR Figure Technology Solutions, Inc.
$SPOT Spotify Technology S.A.
$IBM INTERNATIONAL BUSINESS MACHINES CORP
$EOG EOG RESOURCES INC
$SNDK Sandisk Corp
$DVN DEVON ENERGY CORP/DE
$TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
$APGE Apogee Therapeutics, Inc.
$LQDA Liquidia Corp
$BW Babcock & Wilcox Enterprises, Inc.
$ALDX Aldeyra Therapeutics, Inc.
$DAWN Day One Biopharmaceuticals, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for ACT CAPITAL MANAGEMENT, LLC including:
Track ACT CAPITAL MANAGEMENT, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for ACT CAPITAL MANAGEMENT, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: ACT CAPITAL MANAGEMENT, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For ACT CAPITAL MANAGEMENT, LLC (SEC CIK: 1442273), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in ACT CAPITAL MANAGEMENT, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.